|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALDH1A2 |
Gene summary for ALDH1A2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALDH1A2 | Gene ID | 8854 |
| Gene name | aldehyde dehydrogenase 1 family member A2 | |
| Gene Alias | RALDH(II) | |
| Cytomap | 15q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0001523 | UniProtAcc | O94788 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8854 | ALDH1A2 | AEH-subject1 | Human | Endometrium | AEH | 1.10e-13 | -4.57e-01 | -0.3059 |
| 8854 | ALDH1A2 | AEH-subject2 | Human | Endometrium | AEH | 1.53e-22 | -5.66e-01 | -0.2525 |
| 8854 | ALDH1A2 | AEH-subject3 | Human | Endometrium | AEH | 5.48e-24 | -5.70e-01 | -0.2576 |
| 8854 | ALDH1A2 | AEH-subject4 | Human | Endometrium | AEH | 7.86e-04 | -2.26e-01 | -0.2657 |
| 8854 | ALDH1A2 | AEH-subject5 | Human | Endometrium | AEH | 6.64e-29 | -5.96e-01 | -0.2953 |
| 8854 | ALDH1A2 | EEC-subject1 | Human | Endometrium | EEC | 3.67e-09 | -4.19e-01 | -0.2682 |
| 8854 | ALDH1A2 | EEC-subject2 | Human | Endometrium | EEC | 9.07e-29 | -5.89e-01 | -0.2607 |
| 8854 | ALDH1A2 | EEC-subject3 | Human | Endometrium | EEC | 9.67e-36 | -5.96e-01 | -0.2525 |
| 8854 | ALDH1A2 | EEC-subject4 | Human | Endometrium | EEC | 1.06e-29 | -5.87e-01 | -0.2571 |
| 8854 | ALDH1A2 | EEC-subject5 | Human | Endometrium | EEC | 4.08e-29 | -6.10e-01 | -0.249 |
| 8854 | ALDH1A2 | GSM5276934 | Human | Endometrium | EEC | 9.50e-27 | -5.40e-01 | -0.0913 |
| 8854 | ALDH1A2 | GSM5276935 | Human | Endometrium | EEC | 1.02e-37 | -6.42e-01 | -0.123 |
| 8854 | ALDH1A2 | GSM5276937 | Human | Endometrium | EEC | 1.36e-07 | -4.19e-01 | -0.0897 |
| 8854 | ALDH1A2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 5.26e-30 | -6.49e-01 | -0.1869 |
| 8854 | ALDH1A2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.98e-27 | -6.49e-01 | -0.1875 |
| 8854 | ALDH1A2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.97e-28 | -6.34e-01 | -0.1883 |
| 8854 | ALDH1A2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.09e-32 | -5.78e-01 | -0.1934 |
| 8854 | ALDH1A2 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.98e-39 | -6.44e-01 | -0.1917 |
| 8854 | ALDH1A2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 9.37e-40 | -6.49e-01 | -0.1916 |
| 8854 | ALDH1A2 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 7.60e-18 | -5.23e-01 | -0.1269 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
| GO:003052210 | Endometrium | AEH | intracellular receptor signaling pathway | 60/2100 | 265/18723 | 7.16e-08 | 3.77e-06 | 60 |
| GO:00506738 | Endometrium | AEH | epithelial cell proliferation | 84/2100 | 437/18723 | 4.88e-07 | 1.94e-05 | 84 |
| GO:004873216 | Endometrium | AEH | gland development | 83/2100 | 436/18723 | 8.62e-07 | 3.11e-05 | 83 |
| GO:00147065 | Endometrium | AEH | striated muscle tissue development | 75/2100 | 384/18723 | 1.06e-06 | 3.62e-05 | 75 |
| GO:00016556 | Endometrium | AEH | urogenital system development | 67/2100 | 338/18723 | 2.30e-06 | 6.76e-05 | 67 |
| GO:00506788 | Endometrium | AEH | regulation of epithelial cell proliferation | 73/2100 | 381/18723 | 3.04e-06 | 8.44e-05 | 73 |
| GO:00720015 | Endometrium | AEH | renal system development | 61/2100 | 302/18723 | 3.43e-06 | 9.24e-05 | 61 |
| GO:00323557 | Endometrium | AEH | response to estradiol | 34/2100 | 141/18723 | 1.13e-05 | 2.53e-04 | 34 |
| GO:00018224 | Endometrium | AEH | kidney development | 57/2100 | 293/18723 | 2.25e-05 | 4.35e-04 | 57 |
| GO:00487625 | Endometrium | AEH | mesenchymal cell differentiation | 46/2100 | 236/18723 | 1.27e-04 | 1.74e-03 | 46 |
| GO:00604853 | Endometrium | AEH | mesenchyme development | 54/2100 | 291/18723 | 1.34e-04 | 1.83e-03 | 54 |
| GO:003166716 | Endometrium | AEH | response to nutrient levels | 78/2100 | 474/18723 | 3.26e-04 | 3.64e-03 | 78 |
| GO:00488635 | Endometrium | AEH | stem cell differentiation | 40/2100 | 206/18723 | 3.67e-04 | 3.99e-03 | 40 |
| GO:006100810 | Endometrium | AEH | hepaticobiliary system development | 31/2100 | 150/18723 | 5.41e-04 | 5.45e-03 | 31 |
| GO:00351073 | Endometrium | AEH | appendage morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
| GO:00351083 | Endometrium | AEH | limb morphogenesis | 29/2100 | 138/18723 | 6.06e-04 | 5.94e-03 | 29 |
| GO:00030072 | Endometrium | AEH | heart morphogenesis | 45/2100 | 246/18723 | 6.41e-04 | 6.23e-03 | 45 |
| GO:0048738 | Endometrium | AEH | cardiac muscle tissue development | 43/2100 | 236/18723 | 9.06e-04 | 8.30e-03 | 43 |
| GO:00487366 | Endometrium | AEH | appendage development | 33/2100 | 172/18723 | 1.41e-03 | 1.18e-02 | 33 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALDH1A2 | SNV | Missense_Mutation | c.46N>A | p.Pro16Thr | p.P16T | O94788 | protein_coding | deleterious_low_confidence(0.01) | benign(0.007) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
| ALDH1A2 | SNV | Missense_Mutation | novel | c.875N>T | p.Pro292Leu | p.P292L | O94788 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ALDH1A2 | SNV | Missense_Mutation | c.1234N>G | p.Arg412Gly | p.R412G | O94788 | protein_coding | deleterious(0.03) | probably_damaging(0.954) | TCGA-C5-A901-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ALDH1A2 | SNV | Missense_Mutation | c.73C>G | p.Leu25Val | p.L25V | O94788 | protein_coding | tolerated_low_confidence(0.24) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| ALDH1A2 | SNV | Missense_Mutation | c.755N>G | p.Ser252Cys | p.S252C | O94788 | protein_coding | deleterious(0.03) | possibly_damaging(0.838) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ALDH1A2 | SNV | Missense_Mutation | c.755N>G | p.Ser252Cys | p.S252C | O94788 | protein_coding | deleterious(0.03) | possibly_damaging(0.838) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| ALDH1A2 | SNV | Missense_Mutation | c.62N>T | p.Ala21Val | p.A21V | O94788 | protein_coding | tolerated_low_confidence(0.07) | benign(0.019) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ALDH1A2 | SNV | Missense_Mutation | c.181G>A | p.Ala61Thr | p.A61T | O94788 | protein_coding | tolerated(0.31) | possibly_damaging(0.617) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ALDH1A2 | SNV | Missense_Mutation | rs563668428 | c.1234N>T | p.Arg412Trp | p.R412W | O94788 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| ALDH1A2 | SNV | Missense_Mutation | rs376965202 | c.1181G>A | p.Arg394Gln | p.R394Q | O94788 | protein_coding | tolerated(0.06) | benign(0.012) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | RETINOL | RETINOL | 9666306 | |
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | hydrochlorothiazide | HYDROCHLOROTHIAZIDE | 29097388 | |
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | atenolol | ATENOLOL | 29097388 | |
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | VITAMIN A | 9666306,11133156 | ||
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | RETINOIDS | 11751205 | ||
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | Bisphosphonates | |||
| 8854 | ALDH1A2 | DRUGGABLE GENOME, ENZYME | RETINOIC ACID | 11306068,15652703,14623241 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |